Systematic Review and Meta-Analysis on PCSK9 Inhibitors and Endothelial Function

Christina Antza's 2026 systematic review and meta-analysis synthesizes evidence on the effect of PCSK9 inhibitors on vascular endothelial dysfunction. The work includes 8 eligible articles, with a meta-analysis of 5 studies involving 415 participants. The primary outcome measured was changes in flow-mediated dilation (FMD), comparing PCSK9 inhibitors to placebo.

Use Cases

• Conducting a meta-analysis on the effect of PCSK9 inhibitors on flow-mediated dilation (FMD) based on the described study protocol.
• Comparing treatment outcomes between alirocumab and evolocumab for endothelial function based on the reported mean differences.
• Systematically reviewing literature on non-invasive vascular methods for assessing endothelial dysfunction as described in the methodology.

Strengths

• The dataset includes a protocol registered in the Open Science Framework (OSF), which may enhance reproducibility.
• The meta-analysis provides specific quantitative results, such as a mean difference (MD) of 1.31 for evolocumab with a 95% confidence interval.

Limitations

• The dataset is a 175.1 KB DOCX file, indicating a very limited scope and likely containing only the manuscript text rather than raw data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for data-driven tasks.

Provenance

Source

figshare

Collection Method

Systematic literature review of Embase, Ovid MEDLINE, and CENTRAL databases.

Freshness

Last updated 2026-05-06 09:57:05; freshness should be verified.